Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Therapy of deep mycoses].

P Aubry, P Capdevielle, C Gras

    Medecine Tropicale : Revue Du Corps De Sante Colonial
    |July 1, 1986
    PubMed
    Summary

    In 1985, treatment options for deep mycosis were limited. Amphotericin B was the primary intravenous drug, while others like ketoconazole had specific uses and limitations.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Angioplasty of an anomalous coronary artery : A complex procedure ?]

    Annales de cardiologie et d'angeiologie·2024
    Same author

    Bulletin de la Societe de pathologie exotique (1990)·2024
    Same author

    Bulletin de la Societe de pathologie exotique (1990)·2024
    Same author

    [ANOCOR registry].

    Annales de cardiologie et d'angeiologie·2023
    Same author

    [Cryptogenic stroke management : where are we ?]

    Annales de cardiologie et d'angeiologie·2021
    Same author

    [Renal cell carcinoma in the department of Hérault: Results over a 30 year period].

    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2020

    Area of Science:

    • Medical Mycology
    • Pharmacology

    Context:

    • In 1985, therapeutic options for deep mycosis were restricted.
    • Established antifungal agents included amphotericin B, 5-fluorocytosine, and ketoconazole.
    • Potassium iodide saw limited use.

    Purpose:

    • To review the landscape of available antifungal drugs for deep mycosis in 1985.
    • To outline the clinical applications and limitations of existing treatments.
    • To mention emerging antifungal agents.

    Summary:

    • Amphotericin B (Fungizone) was the preferred intravenous treatment for invasive aspergillosis and cryptococcosis.
    • 5-fluorocytosine (Ancotil) was used adjunctively, not as monotherapy.
    • Ketoconazole (Nizoral) was recommended for specific mycoses and prophylaxis, with noted limitations in cerebrospinal fluid penetration and efficacy in immunocompromised patients.
    • Newer agents like itraconazole and fluconazole were under investigation.

    Impact:

    • Highlights the historical context of antifungal drug availability and usage.
    • Underscores the challenges in treating deep fungal infections prior to newer drug development.
    • Provides a baseline for understanding advancements in antifungal therapy.

    Related Experiment Videos